Completed
AZT and Bone Marrow Transplantation for HIV Prevention in Lymphoma Patients
What is being tested
Zidovudine
Drug
Who is being recruted
Blood-Borne Infections+25
+ Urogenital Diseases
+ Genital Diseases
From 12 to 50 Years
+7 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study is about evaluating the use of a drug called Azidothymidine (AZT) in treating Human Immunodeficiency Virus (HIV) infection in patients who are also receiving a bone marrow transplant. The study focuses on individuals who have HIV and a specific type of cancer known as large cell/diffuse histiocytic lymphoma. The goal is to see if AZT can prevent the reinfection of donor cells in these patients. This research is important as it could potentially improve treatment options for HIV patients undergoing bone marrow transplants.
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 12 to 50 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesHemic and Lymphatic DiseasesImmunologic Deficiency SyndromesImmune System DiseasesImmunoproliferative DisordersInfectionsLymphatic DiseasesLymphomaLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypeRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralHistiocytosisHistiocytic Disorders, MalignantLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexLymphoma, Non-HodgkinHIV InfectionsDendritic Cell Sarcoma, Interdigitating
Criteria
5 inclusion criteria required to participate
Patients must be HTLV III antibody positive by ELISA or Western blot or HTLV III viremia
Patients must be at high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC)
Patient must be a good risk candidate for bone marrow transplant
Patient must have an HIV seronegative identical twin to serve as a bone marrow donor
Show More Criteria
2 exclusion criteria prevent from participating
Other anti-retroviral agents are excluded
Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Johns Hopkins Hemapheresis Treatment Ctr
Baltimore, United StatesOpen Johns Hopkins Hemapheresis Treatment Ctr in Google MapsCompletedOne Study Center